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Mini-abstract:
This narrative review considers the key challenges facing healthcare professionals and policymakers
responsible for providing care to our older people in relation to bone health, and proposes globally
relevant solutions to those challenges.
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Abstract Page
Abstract:
Introduction: This narrative review considers the key challenges facing healthcare professionals and
policymakers responsible for providing care to populations in relation to bone health. These
challenges broadly fall into 4 distinct themes:
1. Case-finding and management of individuals at high risk of fracture
2. Public awareness of osteoporosis and fragility fractures
3. Reimbursement and health system policy
4. Epidemiology of fracture in the developing world
Methods: Findings from cohort studies, randomised controlled trials, systematic reviews and metaanalyses, in addition to current clinical guidelines, position papers and national and international
audits are summarised, with the intention of providing a prioritised approach to delivery of optimal
bone health for all.
Results: Systematic approaches to case-finding individuals who are at high risk of sustaining fragility
fractures are described. These include strategies and models of care intended to improve case-finding
for individuals who have sustained fragility fractures, those undergoing treatment with medicines
which have an adverse effect on bone health, and people who have diseases whereby bone loss and,
consequently, fragility fractures are a common comorbidity. Approaches to deliver primary fracture
prevention in a clinically effective and cost-effective manner are also explored.
Public awareness of osteoporosis is low worldwide. If older people are to be more pro-active in the
management of their bone health, that needs to change. Effective disease awareness campaigns have
been implemented in some countries, but need to be undertaken in many more. A major need exists
to improve awareness of the risk that osteoporosis poses to individuals who have initiated treatment,
with the intention of improving adherence in the long-term. A multisector effort is also required to
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support patients and their clinicians to have meaningful discussions concerning the risk-benefit ratio
of osteoporosis treatment.
With regard to prioritisation of fragility fracture prevention in national policy, there is much to be
done. In the developing world, robust epidemiological estimates of fracture incidence are required to
inform policy development.
Conclusion: As the aging of the Baby Boomer generation is upon us, this review provides a
comprehensive analysis of how bone health can be improved worldwide for all.
Keywords:
Fragility fracture, osteoporosis, case-finding, disease awareness, policy, prioritization, secondary
prevention, primary prevention
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Text

Introduction
In 2016, the first of the Baby Boomer generation entered their eighth decade of life. Consequently,
the next ten years will bear witness to a significant increase in the number of individuals living with
osteoporosis and experiencing the morbidity consequent upon fragility fractures. Fragility fractures
can be defined as fractures which result from a fall from a standing height or less, or that present in
the absence of trauma. The most common fragility fractures occur at the hip, wrist, spine, humerus or
pelvis. As such, it is timely to take stock of the key challenges facing healthcare professionals and
policymakers responsible for providing care for populations in relation to bone health, and to identify
solutions that will reduce fracture rates and ameliorate their personal and societal burden. These
challenges broadly fall into 4 distinct themes:
1. Case-finding and management of individuals at high risk of fracture
2. Public awareness of osteoporosis and fragility fractures
3. Reimbursement and health system policy
4. Epidemiology of fracture in the developing world
This narrative review explores each of these themes in terms of current gaps in delivery of best clinical
practice, levels of public awareness, appropriateness of funding and policy arrangements, and
characterisation of the current and future burden of disease in the developing world. Most
importantly, the work of innovators who have successfully addressed each challenge will be reviewed.
Clinically effective and cost-effective models of care have been developed in many countries to case
find and manage individuals who are at high risk of sustaining fragility fractures. Award winning public
awareness campaigns have been implemented which empower individuals who are living with
osteoporosis to be pro-active in seeking medical advice to reduce their own fracture risk. A number
of governments have identified osteoporosis as a national health priority and implemented
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comprehensive quality improvement programs across their national health systems. New
epidemiological studies from Asia and Latin American have begun to quantify the impact of
osteoporosis in the developing world. While there is much to be done, there is reason for optimism.
All of the challenges identified are solvable: now is the time for these solutions to be implemented
throughout the world.

Case-finding and management of individuals at high risk of fracture
During the last 25 years, a broad range of therapeutic options have become available to reduce an
individual’s risk of fragility fracture [1]. These medicines are available as daily, weekly or monthly oral
tablets, or as daily, three-monthly or six-monthly injections or annual infusions, providing patients and
physicians with a uniquely flexible array of dosing regimens. Getting the right treatment to the right
patient at the right time is of paramount importance if fracture rates are to be significantly reduced
as the world’s population ages. This section of the review focuses on strategies to ensure that
individuals who are at high risk of sustaining fragility fractures in general, and hip fractures in
particular, are reliably identified by health systems and treated in accordance with best practice
guidance. Opportunities to systematise case-finding in four scenarios will be considered:
1. Secondary fracture prevention
2. Primary fracture prevention
3. Osteoporosis induced by medicines
4. Diseases associated with osteoporosis
For each scenario, evidence relating to fracture risk in the population in question is considered.
Current levels of case-finding and appropriate osteoporosis management are reviewed. Where
available, analysis of published work describing models of care to implement best practice is
presented. Finally, selected examples of clinical guidelines and recommendations made therein are
highlighted.
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Secondary fracture prevention
Secondary fracture prevention is an obvious first step in the development of a systematic approach to
prevention of all fragility fractures caused by osteoporosis. Since the 1980s, it has been known that
up to one half of hip fracture patients have already sustained a previous fracture [2-5]. Meta-analyses
have shown that individuals who have sustained a fracture are at approximately double the risk of
sustaining subsequent fractures, as compared to their fracture-free peers [6, 7]. Accordingly, the
notion that fracture begets fracture is well-established in the literature and well represented in clinical
guidelines for osteoporosis in many countries [8, 9]. Further, subsequent fractures appear to occur
rapidly after an index fracture. In 2004, Johnell et al examined the pattern of fracture risk following a
prior fracture at the spine, shoulder or hip [10]. During 5 years of follow-up, one third of all subsequent
fractures occurred within the first year after fracture, and less than 9% of all subsequent fractures
occurred in the fifth year.
The effectiveness of the broad range of currently available osteoporosis treatments has been
comprehensively reviewed elsewhere [1]. Cochrane Collaboration systematic reviews have evaluated
alendronate [11], etidronate [12] and risedronate [13] specifically in the secondary fracture
prevention context for treatment of postmenopausal women, and Cochrane protocols have been
published for zoledronate [14] and denosumab [15]. The findings of the Cochrane reviews for the
bisphosphonates which were statistically significant are summarised in table 1. The methodology used
for pooling of results from the individual trials included in the Cochrane reviews has been described
elsewhere [16]. When the relative risk reduction (RRR) for a particular agent was significant (p<0.05),
the absolute risk reduction (ARR) and number needed to treat (NNT) were calculated. For these
calculations, the Cochrane authors based the 5-year risk of fracture in the untreated population on
the FRACTURE Index (FI) [17], and the lifetime and 5-year age-specific risks in the untreated population
on the model by Doherty et al for predicting osteoporotic fractures in postmenopausal women [18].
Other osteoporosis treatments have been evaluated for secondary fracture prevention in randomised
controlled trials (RCTs) or sub-analyses of RCTs:
7

•

Zoledronate: The HORIZON Recurrent Fracture Trial (RFT) evaluated zoledronate in the
treatment of individuals who had sustained a hip fracture [19]. Statistically significant
reductions were observed for any new clinical fracture (RRR 35% [95% CI 16-50%], ARR 5.3%),
clinical non-vertebral fracture (RRR 27% [95% CI 2-45%], ARR 3.1%) and new clinical vertebral
fracture (RRR 46% [95% CI 8-68%], ARR 2.1%). A non-significant trend towards reduction in
hip fracture (RRR 30% [95% CI -19-59%], ARR 1.5%) was observed. The safety analysis revealed
a statistically significant reduction in deaths from any cause for the individuals treated with
zoledronate (RRR 28% [95% CI 7-44%], ARR 3.7%). A sub-group analysis of the HORIZON
Pivotal Fracture Trial (PFT) observed a comparable effect of zoledronate treatment on the
incidence of new vertebral and non-vertebral fractures for individuals with and without
prevalent vertebral fracture at baseline [20].

•

Denosumab: A post-hoc analysis of the FREEDOM study evaluated denosumab for secondary
fracture prevention [21]. A statistically significant reduction in the incidence of any
subsequent fracture (RRR 39% [95% CI 28-49%], ARR 6.8%) was observed, with similar efficacy
in those who had prior vertebral fractures (RRR 35%, ARR 6.6%) or non-vertebral fractures
(RRR 34%, ARR 6.1%) at baseline which was highly significant (p<0.0001 for both groups).

•

Raloxifene: Among the sub-group of women in the MORE study who had a vertebral fracture
at baseline, those receiving the licensed 60 mg dose of raloxifene sustained significantly fewer
new vertebral fractures compared to placebo (RRR 30% [95% CI 20-50%], ARR 6%) [22].
However, raloxifene did not demonstrate a statistically significant reduction in the incidence
of non-vertebral or hip fractures.

•

Teriparatide: In women with postmenopausal osteoporosis and at least one vertebral fracture
at baseline [23], teriparatide 20 µg per day significantly reduced the incidence of new
vertebral fractures (RRR 65% [95% CI 45-78%], ARR 9.3%) and non-vertebral fragility fractures
(RRR 53% [95% CI 12-75%], ARR 2.9%). However, the definition of non-vertebral fracture was
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not directly comparable to that used in other studies, and teriparatide did not demonstrate a
statistically significant reduction in the incidence of hip fractures.
•

Strontium ranelate: Strontium ranelate significantly reduced the incidence of new vertebral
fracture (RRR 41% [95% CI 27-52%], ARR 11.9%) but not non-vertebral fractures in women
with postmenopausal osteoporosis and at least one vertebral fracture at baseline [24]. A
pooled analysis of the SOTI and TROPOS study populations reported a statistically significant
reduction in the incidence of first vertebral fracture (RRR 46% [95% CI 19-63%], ARR 7.6%)
among women with a prevalent non-vertebral fracture, who did not have a prevalent
vertebral fracture [25].

A pre-planned sub-analysis of postmenopausal women with

osteopenia and a prevalent vertebral fracture, in the combined studies, reported a significant
reduction in the incidence of new vertebral fractures (RRR 37% [95% CI 11-56%], ARR 8.1%)
[26].
In light of the diverse array of effective osteoporosis treatments which are available to reduce future
fracture risk, it is of great concern that a pervasive and persistent secondary prevention care gap is
evident throughout the world. The International Osteoporosis Foundation (IOF) Capture the Fracture®
Program website provides an up-to-date bibliography of all PubMed cited secondary prevention audits
and surveys, undertaken internationally, nationally, regionally and locally [27]. Studies from all regions
of the world feature on the website:
•

Africa: South Africa

•

Asia: China, Hong Kong, Japan, Malaysia, Singapore, South Korea, Taiwan, Thailand.

•

Europe: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, The Netherlands,
Norway, Sweden, Switzerland, UK

•

Latin America: Brazil

•

Middle East: Israel, Saudi Arabia

•

North America: Canada, USA
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•

Oceania: Australia, New Zealand

In response to this widely documented care gap, models of care have been developed in many
countries to ensure that fragility fracture patients receive secondary preventive care – which include
both osteoporosis management and intervention to prevent falls – in a consistent and reliable fashion.
The most common models are referred to as Orthogeriatrics Services (aka Orthopaedic-Geriatric CoCare Services or Geriatric Fracture Centers) and Fracture Liaison Services (FLS).
The complementary roles of Orthogeriatrics Services and FLS are nicely illustrated in consensus
guidelines from the UK. In 2007, the British Orthopaedic Association (BOA) and the British Geriatrics
Society (BGS) published The Care of Patients with Fragility Fracture (aka ‘The Blue Book’), with
contributions from representatives of the Age Anaesthesia Association, Faculty of Public Health,
Society for Endocrinology, Royal College of Nursing and the UK National Osteoporosis Society [28].
The first section of The Blue Book advocated widespread implementation of coordinated,
multidisciplinary care for hip fracture patients through establishment of Orthogeriatrics Services in
hospitals. Such models of care are designed to expedite surgery, ensure optimal management of the
acute phase through adherence to a care plan overseen by senior staff in orthopaedics and
geriatrics/internal medicine, and deliver secondary fracture prevention through osteoporosis
management and falls prevention. Implementation of Orthogeriatrics Services has gained momentum
globally in recent years, supported by development of national hip fracture registries to enable
benchmarking of the quality of hip fracture care against best practice guidelines [29].
The UK National Health Service (NHS) provides a large scale illustration of the impact that
Orthogeriatrics Services, supported by a National Hip Fracture Database (NHFD) [30] and quality
incentives from government [31], can have upon post-hip fracture secondary preventive care. The UK
NHFD is currently the largest ongoing audit of hip fracture care in the world, with more than 454,000
case records entered since it was launched in tandem with the Blue Book in 2007 (Personal
communication: C. Boulton). The 2015 NHFD Annual Report described the care of 64,102 people who
10

presented with a hip fracture in 2014, representing nearly 95% of all cases in England, Wales and
Northern Ireland [32]. More than 80% of patients were started on osteoporosis treatment, or were
referred for bone mineral density (BMD) testing or bone clinic assessment. Further, more than 96% of
patients were offered a multifactorial risk assessment to identify and address future falls risk, and
were offered individualised intervention where appropriate.
The second section of the Blue Book called for widespread implementation of FLS. The purpose of an
FLS is to ensure that all patients aged 50 years or over who present to health services with a fragility
fracture undergo fracture risk assessment and receive osteoporosis treatment in accordance with
national guidelines. The FLS would also refer older patients into local falls prevention services. In terms
of a ‘division of labour’, Orthogeriatrics Services typically deliver secondary preventive care for hip
fracture patients and FLS deliver secondary preventive care for non-hip fragility fracture patients (e.g.
wrist, humerus, pelvis and those vertebral fractures which come to clinical attention).
During the last 15 years, studies describing the design and performance of FLS have been published
from many countries [8]. However, variation in FLS service design and reporting of processes and
outcomes make comparisons between services difficult. In order to establish which specific features
of an FLS are associated with optimal case-finding and implementation of osteoporosis treatment
guidelines, Australian investigators undertook a systematic review and meta-analysis of the secondary
fracture prevention literature [33]. The various FLS were classified into four types:
•

Type A or 3i FLS models which deliver identification, investigation and initiation of
interventions.

•

Type B or 2i FLS models which deliver identification and investigation, but rely on initiation of
interventions by the primary care physician (PCP).

•

Type C or 1i FLS models which deliver identification and an alert to the PCP that further
investigations are needed, but rely on the PCP to organise those investigations and initiate
interventions, where warranted.
11

•

Type D or ‘Zero i’ models which provide osteoporosis education to the patient, but do not
alert or educate the PCP.

The proportion of patients undergoing BMD testing and receiving osteoporosis treatment for each
type of FLS model is shown in table 2. Clearly, Type A (3i) and Type B (2i) FLS models result in
considerably more fracture patients being investigated and initiated on treatment. Whilst practically
all osteoporosis treatment guidelines worldwide recommend that fragility fracture patients should be
assessed for osteoporosis, the proportion that should receive osteoporosis treatment remains an
ongoing matter of debate. In 2005, the first UK National Institute for Health and Care Excellence (NICE)
technology appraisal on osteoporosis treatments for the secondary prevention of fracture estimated
that up to 70% of women over 50 years of age with a fragility fracture could benefit from treatment
[34]. This analysis assumed that all women aged 75 years or over could be indicated for treatment in
the absence of BMD testing and a smaller proportion of younger women. Given that a minority of
fracture patients in this age group are likely to suffer early post-fracture mortality, 50% to 70% might
represent a pragmatic estimate of what would constitute a clinically appropriate range for treatment
rates among all fragility fracture patients aged 50 years or over.
A meta-analysis has reported that osteoporosis treatments are associated with reduced mortality
when taken by individuals who are at high risk of fracture [35]. This finding could be influenced by
referral bias: individuals who are perceived to have a low life expectancy may be less likely to receive
osteoporosis treatments. In 2014, however, in addition to a beneficial effect on fracture rates, care
delivered by an FLS was shown to reduce mortality of fracture patients [36]. The FLS model of care has
also been subject to cost-effectiveness modelling. An example of this approach is a cohort health-state
transition model (a Markov model) developed to evaluate the Glasgow FLS in Scotland, UK [37]. The
model demonstrated that 18 fractures were prevented, including 11 hip fractures, and £21,000
(€26,250, US$30,000) was saved per 1,000 patients managed by the Glasgow FLS vs ‘usual care’ in the
UK.
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It should be noted that vertebral fractures make up only a small proportion of FLS case loads [38-45],
as shown in table 3. This is an important shortcoming which must be addressed because vertebral
fractures are the most common fragility fracture and are underdiagnosed throughout the world [46].
Further, the prevalence of vertebral fractures among individuals who sustain hip fractures has been
shown to be very high. Studies from Japan and Spain reported that 78% and 63% of hip fracture
patients had prevalent vertebral fractures, respectively [47, 48]. Vertebral fractures were defined by
the Japanese and Spanish investigators on the basis of the criteria established by The Japanese Society
for Bone and Mineral Research [49] and Genant [50], respectively. It should be noted that while clinical
vertebral fractures are a risk factor for hip fracture, asymptomatic grade 1 morphometric fractures
have no prognostic value [51]. A considerable volume of imaging with plain radiography, and X-Rays,
CT and MRI scans is undertaken among older people in hospitals worldwide every day. Approaches to
improve vertebral fracture case-finding from such activity has been reviewed elsewhere [52].
Vertebral fracture assessment (VFA) provides a low radiation exposure alternative to standard X-ray
that could be conducted when patients attend for a DXA scan. This approach has been explored in the
FLS setting [53, 54]. Amongst patients presenting with non-vertebral fractures that were assessed by
a FLS, the overall prevalence of vertebral deformity was of the order of a quarter to a fifth (25% [53]
and 20% [54]). VFA identified a substantial burden of prevalent vertebral fractures that had not been
previously documented. The proportion of non-vertebral fracture patients that would be managed
differently as a result of conducting VFA was relatively small (9% [53] and 3% [54]). This is perhaps not
surprising given that the patients investigated had a non-vertebral fracture which triggered FLS
assessment. However, incorporation of VFA into FLS protocols has the potential to reveal two subgroups of non-vertebral fracture patients that may be managed differently as a result of ascertainment
of vertebral fracture status:
•

Patients with ≥ 1 vertebral fracture (grade 2 or higher) and an osteopenic BMD

•

Patients with multiple vertebral fractures and profoundly osteoporotic BMD
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In both cases, knowledge of the presence of vertebral fractures has the potential to impact upon
clinical decision making to optimise care for the individual patient’s circumstances. In 2007, Siris et al
evaluated the combination of ascertaining vertebral fracture status and BMD measurement in fracture
risk prediction [55]. These investigators concluded:
“For any given BMD T-score, the risk of an incident vertebral, non-vertebral fragility, and any
fracture differs by up to twelve times, 2 times, and 7 times, respectively, when information
regarding spine fracture burden is considered. In the absence of knowledge about the
prevalent vertebral fracture status, assessments based solely on BMD may under- or overestimate the true risk of a patient experiencing an incident fracture”.
Further, when clinicians use the FRAX® tool to calculate an individual’s fracture risk, the notes on risk
factors state [56]:
“A special situation pertains to a prior history of vertebral fracture. A fracture detected as a
radiographic observation alone (a morphometric vertebral fracture) counts as a previous
fracture. A prior clinical vertebral fracture or a hip fracture is an especially strong risk factor.
The probability of fracture computed may therefore be underestimated. Fracture probability
is also underestimated with multiple fractures”.
Accordingly, the presence of a vertebral fracture could significantly influence the fracture risk
calculated by FRAX®. Given that an increasing number of clinical guidelines make reference to
intervention thresholds based upon a FRAX® score, the decision to treat or not may be influenced by
knowledge of vertebral fracture status. Another conclusion of the FLS VFA work was that VFA should
ideally be conducted on all patients that are referred for DXA who do not have a clinical fracture
history, in order to improve case-finding of vertebral fractures [53].
Clinical or Quality Standards for FLS have been developed in Canada [57], New Zealand [58] and the
UK [59, 60]. IOF has also developed internationally endorsed standards for FLS in the form of the
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Capture the Fracture® Best Practice Framework (BPF) [61-63]. The Capture the Fracture® BPF
comprises a comprehensive suite of 13 standards:
1. Patient Identification Standard
2. Patient Evaluation Standard
3. Post-fracture Assessment Timing Standard
4. Vertebral Fracture Standard
5. Assessment Guidelines Standard
6. Secondary Causes of Osteoporosis Standard
7. Falls Prevention Services Standard
8. Multifaceted Health and Lifestyle Risk-factor Assessment Standard
9. Medication Initiation Standard
10. Medication Review Standard
11. Communication Strategy Standard
12. Long-term Management Standard
13. Database Standard
The Capture the Fracture® Program encourages FLS throughout the world to apply for Best Practice
Recognition which can result in the FLS featuring on the ‘Map of best practice’ on the Capture the
Fracture® Program website. In 2015, an analysis of the first 60 FLS to apply for Best Practice
Recognition was undertaken to confirm that a single framework with set criteria was able to
benchmark services across healthcare systems worldwide [62]. The FLS represented 6 continents and
were highly heterogeneous in many aspects, serving populations from 20,000 to 15 million individuals,
being a mixture of private and publicly funded systems, and managing vastly different number of
fracture patients at individual sites. The assessment process considered performance of the FLS
against the standards across five domains: (a) patients with hip fractures, (b) patients admitted for
other non-hip fragility fractures, (c) patients seen primarily in the ambulatory setting with fragility
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fractures, (d) patients with vertebral fragility fractures, and (e) organisational and falls services. The
domain-level rankings contributed to an overall ranking of Gold, Silver, Bronze or Black (insufficient)
level of achievements for the FLS, in addition to a score in the range 0 to 5. Overall, 27 hospitals scored
Gold, 23 Silver and 10 Bronze, with care for the hip fracture patients achieving the highest proportion
of gold grading for an individual domain, while vertebral fracture achieved the lowest. The authors
concluded that the BPF was fit-for-purpose as a tool to benchmark performance of FLS globally. At the
time of writing, 174 FLS feature on the map of best practice: 41 ranked Gold, 47 Silver, 20 Bronze and
66 still under review or in development.
Government organisations in several countries have supported implementation of systematic
approaches to fragility fracture care and prevention which prioritise secondary fracture prevention,
including Australia, Canada, New Zealand, Singapore and UK [8, 64]. The overarching strategy
originally developed by the Department of Health in England [65] has informed policy development in
other countries, such as New Zealand [66, 67] as illustrated in figure 1.

Primary fracture prevention
Whilst in many populations approximately 1 in 2 women and 1 in 5 men will sustain a fragility fracture
during their lifetimes after age 50 years [68], at any given point in time, the majority of older people
lack a fracture history. Strategies to develop clinically effective and cost-effective approaches to
primary fracture prevention must first establish the size of the primary prevention population in a
particular jurisdiction. Further, which first fragility fracture is to be prevented will significantly
influence the cost-effectiveness of such strategies, with ‘hip fracture as first fragility fracture’ being an
obvious candidate.
Several studies make quantification of the primary prevention population possible for some European
countries, which have sought to determine the incidence and prevalence of osteoporosis and fragility
fractures among postmenopausal women. In 2011, Gauthier et al developed a disease model that
aimed to estimate the burden of osteoporosis at a national level [69]. This model was validated using
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Swedish data and has since been adapted for France [70], Germany [71], Italy [72], and the UK [73].
As illustrated in table 4, the individual national models identified the number of women aged 50 years
or over in each country based on information from the relevant national statistics organisation. The
proportion of women with a prior history of at least one fragility fracture varied from 10% in France
to almost 23% in Sweden. Consequently, the proportion of fracture-free women – the primary
prevention population – ranged from 77% in Sweden to almost 90% in France.
Studies have not been conducted to determine the proportion of men with a history of at least one
fragility fracture at any skeletal site in the countries mentioned above. However, a compendium of
country-specific reports for the European Union countries did provide estimates of prior hip and
vertebral fracture history for men in 2010 [74]. An associated report suggests that the sum of prior
hip and prior clinical vertebral fractures represents approximately 30% of all prior fragility fractures
[75]. The relative proportions of women and men in the five countries with a prior history of hip or
vertebral fracture in 2010 is shown in table 5 (n.b. the populations of women aged 50 years and over
differ slightly between tables 4 and 5 because of a different data source for the populations being
used in the compendium of country-specific reports). As is well known, more fractures occur in older
women compared to older men, resulting in a higher proportion of older women having a prior
fracture history compared to older men. That being said, approximately one-third of hip fractures
worldwide occur in men, so osteoporosis management of the relatively small proportion of men who
have a prior history of fracture should not, as is often the case, be neglected [76].
While demonstrating cost-effectiveness of a primary fracture prevention strategy is of great
importance in the cost-constrained circumstances in which many health systems currently operate,
providing appropriate clinical care to individuals who are at high risk of sustaining debilitating first
fractures at sites other than the hip should not be ignored. Vertebral fractures result in pain, functional
disability and decreased quality of life, and are also associated with excess mortality [77]. Major non-
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hip, non-vertebral fractures have been demonstrated to be associated with 20% excess mortality
during the first 5 years post-fracture [78].
The secondary fracture prevention care gap has been well documented, as described in the previous
section of this review. While specific studies have not been undertaken in primary fracture prevention,
it seems reasonable to assume that a care gap also exists for the high risk primary prevention
population. A report on osteoporosis in the European Union (EU) published in 2013 documented
national prescribing levels [75]. These data, in combination with an algorithm which calculated the
number of patients who were eligible for treatment in each of the 27 EU member states at the time,
enabled estimation of the potential treatment gap for each country in 2010. This approach assumed
that all those treated were actually eligible for treatment and not at a lower level of risk, so may have
underestimated the treatment gap among high risk patients. In total in the EU, 10.6 million out of 18.4
million women who were eligible received treatment. Among men, 1.7 million men out of the 2.9
million men who were eligible received treatment.
Strategies to prevent first fractures could function through several ‘tracks’. For example, the next two
sections of this review, relating to osteoporosis induced by medicines and diseases associated with
osteoporosis, will, in part, serve to deliver primary fracture prevention in a systematic fashion. The
advent of absolute fracture risk calculators, such as the FRAX® tool, provide a means to stratify
fracture risk in the entire older population. The UK National Osteoporosis Guideline Group (NOGG)
has based its guidance on FRAX®, where an intervention threshold for 40 to 90 year olds is set at a risk
equivalent to that expected in a woman with a prior fracture [79]. Many countries have subsequently
adopted the approach taken by NOGG [9]. The US National Osteoporosis Foundation (NOF) guidance
recommends initiation of treatment in the following three scenarios [80]:
•

In those with hip or vertebral (clinical or asymptomatic) fractures.

•

In those with T-scores ≤−2.5 at the femoral neck, total hip, or lumbar spine by dual energy xray absorptiometry (DXA).
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•

In postmenopausal women and men age 50 or older with low bone mass (T-score between
−1.0 and −2.5, osteopenia) at the femoral neck, total hip, or lumbar spine by DXA and a 10year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability
≥20% based on the US version of FRAX®.

Just as the FLS model of care has been developed to close the secondary prevention care gap,
analogous models now need to be developed to deliver primary fracture prevention in a systematic
fashion. Equipped with knowledge of which medicines induce osteoporosis, what other diseases have
osteoporosis as a common comorbidity, and online access to absolute fracture risk calculators to
stratify fracture risk in the population, the necessary case-finding tools are now available to develop
effective models of care to prevent the first fracture.

Osteoporosis induced by medicines
Many classes of drugs have been shown to adversely affect BMD and/or elevate fracture risk. While
links have not been proven to be causal in every case, the drug classes shown in table 6 have all been
associated with fracture outcomes. It is beyond the scope of this review to describe in detail the
mechanisms of action, epidemiology of BMD loss and/or increase in risk of fragility fractures, and
utility of interventions to prevent bone loss for each drug class. Accordingly, key observations on the
impact of each class on BMD and fracture risk are indicated in table 6, primarily in accordance with
the findings of Panday et al in their 2014 review on medication-induced osteoporosis [81]. Recent
literature reviews specific to each drug class are also cited to provide the reader with a source of more
detailed current information [82-91]. A focus on three commonly used classes – glucocorticoids,
androgen deprivation therapy and aromatase inhibitors – serves to illustrate the potential benefits of
strategies to prevent osteoporosis induced by medicines.

Glucocorticoid-induced osteoporosis
Glucocorticoid (GC)-induced osteoporosis is the most common cause of secondary osteoporosis [92].
Among adults aged 18 years or over it has been estimated that 7.5% have received at least one
prescription for an oral GC [93]. GCs exert their effects on bone quality and bone mass through a
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number of direct effects on osteoblasts, osteoclasts and osteocytes, in addition to indirect effects
mediated through the neuroendocrine system, calcium metabolism and muscle [92]. GC-induced
fractures occur most commonly at sites with significant amounts of cancellous bone, such as the
vertebrae and femoral neck. Among chronic GC users, up to 30-50% of patients may sustain fractures,
depending on the population studied.
Clinical guidelines for the prevention and treatment of GC-induced osteoporosis are available in many
countries. In 2012, the Joint IOF – European Calcified Tissue Society (ECTS) Glucocorticoid-induced
Osteoporosis Guidelines Working Group published a framework for the development of guidelines for
the management of GC-induced osteoporosis [94]. This comprehensive framework reviewed the
epidemiology of GC-induced osteoporosis and fracture risk assessment based on 10-year probabilities
ascertained from FRAX®. A systematic review was performed to assess the efficacy of interventions.
The Working Group proposed management algorithms which could be tailored to context of
healthcare delivery in individual countries.
Despite the widespread availability of licensed medications to prevent and treat GC-induced
osteoporosis, and numerous clinical guidelines to support healthcare professionals to deploy these
interventions, a major care gap exists. In 2014, Albaum et al published a systematic review of studies
undertaken between 1999 and 2013 which reported the proportion of patients on chronic oral GC
therapy who received osteoporosis management [93]. The meta-analysis included studies from North
America, Europe and other regions of the world. The majority of studies (>80%) reported that less
than 40% of chronic oral GC users received BMD testing or osteoporosis therapy. A temporal analysis
concluded that there was little evidence for improvement over time.
Clinicians from the Geisinger health system in the United States identified the GC-induced
osteoporosis care gap among their own GC users, despite educational and process changes which had
been implemented over several years. To overcome this deficiency, a specific Glucocorticoid-Induced
Osteoporosis Program (GIOP) was developed and implemented [95]. The GIOP team included a nurse
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specialist program leader, physician co-leader, nurse specialist care provider, physician consultants
and data manager. The stated goals of GIOP were:
•

Identifying at-risk patients in the Geisinger health system

•

Educating patients

•

Developing/implementing pathways to improve GC-induced osteoporosis diagnosis and
treatment

•

Monitoring GC-induced osteoporosis outcomes

•

Using technology/process flows to ‘make it easy to do the right thing’

Two hundred chronic GS users were seen at baseline, and follow-up visits were scheduled at 6 and 12
months. Key outcomes of the program at 12 months included:
•

Patient retention of knowledge, frequency of exercise, and 25(OH)-vitamin D concentrations
all significantly improved.

•

A significant decrease in GC dose was observed.

•

91% of patients considered at high fracture risk were taking a bisphosphonate or teriparatide,
and 96% of patients overall were adherent to their prescribed regimen of calcium, vitamin D,
and prescription treatment, where indicated.

Geisinger’s GIOP provides an example of a model of care which can reliably deliver best practice in the
prevention and treatment of GC-induced osteoporosis.

Androgen Deprivation Therapy-induced osteoporosis
Prostate cancer is the most common non-cutaneous malignancy. The current lifetime risk of
developing prostate cancer (PC) is estimated to be almost 17% (i.e. 1 in 6 men) [96]. Androgen
Deprivation Therapy (ADT), usually in the form of a gonadotropin-releasing hormone agonist (GnRH),
is a mainstay of treatment of metastatic, locally advanced or recurrent PC. Currently, approximately
one-third of PC patients receive ADT [97]. The purpose of ADT is to reduce serum testosterone to
castrate levels, with the consequent potential to induce osteoporosis and increase fracture risk.
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Clinical guidelines for the prevention and treatment of ADT-induced osteoporosis are available in
many countries. In 2013, the IOF Committee of Scientific Advisors (CSA) Working Group on Cancerinduced Bone Disease published a position paper on cancer-associated bone disease [98]. In relation
to prostate cancer, the pathophysiology and epidemiology of ADT-induced osteoporosis was
reviewed. The role of BMD testing and fracture risk assessment was considered, in addition to analysis
of the evidence-base for the prevention of bone loss and fractures with osteoporosis treatments. An
algorithm for the management of ADT-induced osteoporosis was provided. In 2014, the European
Society for Medical Oncology (ESMO) published clinical practice guidelines relating to bone health in
cancer patients, including PC [99]. The guidelines identified three distinct areas of cancer management
that make consideration of bone health in cancer patients important:
•

Bone metastases are common in many solid tumours, including those of the prostate.

•

Many cancer treatments, including ADT, have effects on reproductive hormones which can
adversely affect the process of normal bone remodelling.

•

On account of the bone marrow micro-environment being intimately involved in metastatic
processes, bone-targeted treatments can reduce metastasis of cancer to bone and so,
potentially, improve survival.

The ESMO guidelines provide a management algorithm and practical recommendations on optimising
bone health for cancer patients.
While the osteoporosis care gap for ADT-induced osteoporosis has not been documented as
comprehensively as is the case for secondary fracture prevention and GC-induced osteoporosis, local
studies from several countries suggest that a gap exists:
•

Canada: In 2012, a cross-sectional survey-based study was conducted involving practicing
urologists and genitourinary radiation oncologists across Canada [100]. The majority of
respondents correctly identified the guideline-concordant frequency of repeat DXA scans
(76.3%), vitamin D (70.3%), and calcium (53.2%) intake and that bisphosphonates/denosumab
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should always be considered for patients with a history of one low-trauma fracture (57.6 %).
However, in practice, only one third (32.5%) reported routinely measuring BMD prior to
starting ADT and routinely measuring BMD 1-2 years following the initiation of ADT (36.6 %).
Less than 5% of respondents routinely used a validated fracture risk assessment tool.
•

India: In 2011, telephone interviews were undertaken with 108 members of the Urological
Society of India. Less than one fifth (19.8%) of urologists routinely measured BMD before
starting ADT. Only half of respondents stated that they advised their patients that
osteoporosis and adverse skeletal events could be a side effect of ADT. While a majority of
urologists (59.6%) frequently used zoledronic acid in their clinical practice, approximately half
of these users prescribed the bisphosphonate to men without knowledge of their BMD status.
Very limited access to BMD testing in India is likely to contribute to this practice, as reported
in the IOF Asia-Pacific Regional Audit published in 2013 [101].

•

United States: Men diagnosed with PC between 2005 and 2007 in the Texas Cancer
Registry/Medicare linked database (n=2,290) were analysed to determine what proportion
underwent BMD testing and/or received osteoporosis treatment [102]. Less than one tenth
(8.6%) underwent DXA within 1 year before and 6 months after initiation of ADT. Among the
approximately 50% of study subjects who were enrolled in the Medicare part D scheme
(n=1,060), 5.6% received bone sparing drugs when started on ADT, and 12.6% received bone
sparing drugs or underwent DXA.

The Kaiser Permanente Healthy Bones Program has specifically focused on delivery of appropriate
osteoporosis assessment to men diagnosed by PC between 2003 and 2007 in the Kaiser Permanente
Southern California health system [97]. The investigators created two study cohorts:
•

Healthy Bones Program (HBP) Group: Any patient with PC who underwent BMD measurement
at most 3 months before their first administration of ADT.

•

Non-HBP Group: All other PC patients.
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Men managed by the HBP group with BMD T-scores ≥ -2.5 received lifestyle advice relating to smoking
cessation, exercise and adequate intake of calcium (1,200 mg/day) and vitamin D (400-800 IU/day).
Men with T-scores < -2.5 were also treated with a bisphosphonate and followed up by an
endocrinologist. The incidence rate of hip fractures per 1,000 person-years was 5.1% (95% CI, 3.0-8.0)
in the HBP Group as compared to 18.1% (95% CI, 10.5-29.0) in the non-HBP Group.
Kaiser Permanente’s HBP provides an example of a model of care which can reliably deliver best
practice in the prevention and treatment of ADT-induced osteoporosis.

Aromatase inhibitor-induced osteoporosis
Breast cancer (BC) is the most common neoplasm in women, and the leading cause of cancer-related
mortality in women [103]. One in eight women will develop BC during their lifetime, and it accounts
for almost a quarter (23%) of total cancer cases and 14% of all cancer-related deaths. Aromatase
inhibitors (AI) are currently considered to be the gold standard adjuvant treatment for
postmenopausal women with hormone receptor-positive BC. The aromatase enzyme converts
androgens into estrogens providing the main source of endogenous estrogens after the menopause.
Thus, bone loss and increased fracture risk is an expected side effect of AI therapy.
Clinical guidelines for the prevention and treatment of AI-induced osteoporosis are available in many
countries. In 2012, the European Society for Clinical and Economical Aspects of Osteoporosis (ESCEO)
published guidance on prevention of bone loss and fractures in postmenopausal women treated with
AIs [85]. Key recommendations included:
•

All women starting AI therapy should be assessed for their baseline risk of sustaining a fragility
fracture, using DXA examination, biochemical assessment and evaluation of all clinical risk
factors with the FRAX® tool.

•

General advice on appropriate levels of physical exercise and vitamin D and calcium intake
should be given.

•

Antiresorptive treatment should be offered to the following groups:
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-

Pre-menopausal women with ovarian suppression undergoing tamoxifen or AI
therapy with T-score < -1.0 or presence of ≥ 1 vertebral fracture or history of fragility
fracture (any site, irrespective of BMD).

-

Post-menopausal women with history of personal fragility fracture (any site) or age ≥
75 years old (irrespective of BMD).

-

Post-menopausal women with T-score < -2.5 or < -1.5 + ≥ 1 clinical risk factor or Tscore < -1.0 + ≥ 2 clinical risk factors or FRAX® 10-year risk of hip fracture ≥3%.

While the osteoporosis care gap for AI-induced osteoporosis has not been documented as
comprehensively as is the case for secondary fracture prevention and GC-induced osteoporosis,
studies from the UK [104] and United States [105] have again identified a care gap. The US study
reported that less than half (44%) of women underwent BMD testing within 14 months of continuous
AI use for at least 9 months [105]. Furthermore, 75% and 66% of women failed to have BMD tests
done during the second and third annual time periods after continuous AI use for almost 2 and 3 years,
respectively.
Quality improvement initiatives from Italy [106] and UK [104] provide examples of efforts to manage
bone health of women treated with AI therapy in a systematic fashion. Investigators from London, UK
used a text recognition system installed on the computers of secretaries in the oncology department
to automate referral of women age 50 to 80 years who were undergoing treatment for BC to an
Osteoporosis Nurse Specialist (ONS) [104]. In addition, text was automatically inserted into letters
from the oncology department to patients’ PCP, advising them that their patient would receive an
osteoporosis assessment and management, where warranted. The proportion of BC patients referred
for osteoporosis assessment increased 10-fold upon implementation of this system.

Diseases associated with osteoporosis
Many diseases predispose an individual to developing osteoporosis and/or sustaining fragility
fractures. These comprise a broad array of disorders including autoimmune, digestive and
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gastrointestinal, endocrine and hormonal, hematological, neurological, mental illness, cancer and
AIDS/HIV. An overview of associations between several common diseases [107-112] and bone loss
and/or fracture risk [113-120], and current evidence for the existence of an osteoporosis care gap
[121-125] for individuals with these diseases is provided in table 7. For some of the diseases, the
frequent presence of osteoporosis as a comorbidity has prompted development of disease-specific
clinical guidelines intended to reduce fracture risk [126-128]. Where guidelines have been developed,
efforts should be made throughout the world to implement their recommendations to improve the
bone health of these individuals as a standard component of management of the particular disease.
With regard to diabetes, in light of the enormous number of individuals already affected, evidencebased guidelines for the management of osteoporosis in type 2 diabetes must be drafted and
implemented as soon as possible. Similarly, evidence-based guidelines for the management of
osteoporosis - and falls risk - in dementia must be drafted and implemented globally.

Public awareness of osteoporosis and fragility fractures
Throughout the world, public awareness of osteoporosis and the fragility fractures it causes, is low. If
the projected dramatic increase in the number of individuals sustaining fragility fractures in the first
half of this century is to be attenuated, awareness must be increased. This section of the review will
consider three key aspects of raising awareness and eliminating current confusion among lay people:
•

The importance of staying on treatment

•

Public awareness of osteoporosis and fracture risk

•

Public awareness of benefits versus risks of osteoporosis treatment

A determined global effort is required, involving healthcare professionals and their organisations,
patient societies and policymakers, to provide the public with clear, consistent and compelling
messages regarding bone health. Focusing on these three issues provides a framework to achieve that
objective.
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Adherence to treatment
There are two measures of adherence to treatment which are commonly used in studies; maximal
achievement of these often requires contribution from prescriber as well as the patient:
•

Persistence: Defined as either the time to treatment discontinuation or as the proportion of
patients that at a certain time point still fill prescriptions without a gap in refills longer than
an allowed period of time (e.g., 30, 60 or 90 days).

•

Compliance: Defined as the ability of a patient to adhere to the dosing, timing and conditions
described by the prescriber or in accordance with the medicine’s patient information leaflet.
One indirect measure of compliance is the medication possession ratio (MPR). MPR is usually
defined as the number of days of medication available to the patient, divided by the number
of days of observation.

Osteoporosis is a long-term condition which, therefore, requires a long-term management plan.
Frequently, individuals at high risk of sustaining fragility fractures who have been initiated on
osteoporosis treatment cease to take that treatment within the first year [129]. This problem should
come as no surprise to our field as this phenomenon has been widely reported for other classes of
medicines for treatment of chronic diseases, such as anti-hypertensives and statins. That being said,
osteoporosis is somewhat unique in medicine in terms of the flexibility of dosing options that are
available to patients, including daily, weekly or monthly tablets, and daily, quarterly, six-monthly or
annual injections or infusions. Accordingly, a first important step in raising awareness of osteoporosis
is to ensure that individuals who have been initiated on drug therapy understand why their physician
has decided that treatment is warranted.
In 2013, the Medication Adherence and Persistence Special Interest Group of the International Society
For Pharmacoeconomics and Outcomes Research (ISPOR) undertook a systematic literature review of
interventions to improve osteoporosis medication adherence [130]. Key findings included:
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•

Patients were most persistent with medications which had the least frequent dosing
regimens.

•

Electronic prescriptions in combination with verbal counselling were associated with a 2.6fold improvement in short-term compliance compared to verbal counselling alone.

•

With regard to patient education based interventions, the largest and least biased studies
reviewed showed only marginal improvement in adherence.

An emerging body of evidence suggests that osteoporosis treatment initiated by a FLS for fragility
fracture patients is more likely to be adhered to than regimens for patients managed in other settings.
In 2011, the FLS at the University Hospital of St. Etienne, France evaluated adherence among 155
fracture patients who were initially prescribed a specific osteoporosis treatment by the FLS [131].
Among the 90% of patients (n=140) who actually used the prescription to begin treatment, 80% were
still taking treatment at 12 months. In terms of longer term persistence, after 27.4 months (±11.7
months) of follow-up, 68% of patients were persistent with their treatment. Among the persistent
patients, 87% reported that they continued to comply with both the treatment dosing and
administration conditions. In 2014, similar findings were reported by the FLS at Amiens University
Hospital, France [132]. The proportion of patients initially treated by the FLS who continued to take
treatment at 12 months and 18 months was 74% and 67%, respectively. A report from the FLS at
Concord Repatriation General Hospital, Sydney, Australia compared adherence among patients
initiated on treatment by the FLS who were subsequently followed up by either the FLS or local PCPs
[133]. Persistence at 24 months was similar in both groups leading the investigators to conclude that
the main function of an FLS is to initiate a management plan for osteoporosis after fractures occur. If
effective communication between the FLS and local PCPs is established, PCPs are well-placed and
willing to manage osteoporosis care in the longer term.

Awareness of osteoporosis and fracture risk
In recent years, numerous studies have been conducted to characterise public awareness and
understanding of osteoporosis, fracture risk and the link between them. In 2008, investigators from
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Kaiser Permanente Northwest, USA sought to evaluate stakeholder perspectives on post-fracture
osteoporosis care delivered by an outreach program which targeted patients and PCPs [134].
Qualitative evaluation was undertaken by semi-structured, in-depth individual interviews with women
aged 67 years or older who had sustained a clinical fracture (n=10), PCPs (n=9), quality and other
healthcare managers (n=20), and orthopaedic clinicians and staff (N=28). As compared to other
common conditions, PCPs noted, and patients demonstrated, a lack of understanding of osteoporosis
and its management, which included:
•

Fatalism: Osteoporosis being confused with osteoarthritis, so promoting the notion that
osteoporosis is an inevitable but benign consequence of aging.

•

Media influence: PCPs noted that patients would often seek BMD testing in response to
suggestions to do so in the popular press.

•

Long-term treatment: Patients expressed concern regarding the duration of treatment with
specific osteoporosis therapies, and uncertainty regarding the consequence of stopping
treatment.

In 2013, investigators from Toronto, Canada evaluated fragility fracture patients’ understanding of the
link between osteoporosis and fractures [135]. The participants were drawn from a database created
by the provincial post-fracture screening programme, a component of the Ontario Osteoporosis
Strategy. The main outcome for the study was fracture patients’ response to the question ‘Do you
think your broken bone could have been caused by having osteoporosis (thin or brittle bones)?’ The
range of responses that were not in the affirmative were collapsed into one category ‘did not make
the link’. At baseline, 93% (1,615/1,735) of fracture patients did not believe that their fracture could
have been caused by osteoporosis. At follow-up, only 8.2% changed their perception. In adjusted
analyses, several baseline characteristics were shown to be predictive of individuals who would be
more likely to make the link. These included individuals who had sustained a previous fracture (odds
ratio [OR] 1.7, 95% CI, 1.2-2.6), perception of osteoporosis pharmacotherapy benefits (OR 1.2, 95% CI,
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1.0-1.5), diagnosis of rheumatoid arthritis (OR 2.6, 95% CI, 1.4-4.9) and perception of bones as ‘thin’
(OR 8.2, 95% CI, 5.1-13.1).
The international GLOW study has compared self-perception of fracture risk with actual risk among
more than 60,000 postmenopausal women in 10 countries in Europe, North America, and Australia
[136]. Key findings included:
•

Among women reporting a diagnosis of osteopenia or osteoporosis, only 25% and 43%,
respectively, thought their fracture risk was increased.

•

Among women whose actual fracture risk was increased based on the presence of any one of
seven risk factors for fracture, the proportion who recognized their increased risk ranged from
19% for smokers to 39% for current users of glucocorticoid medication.

•

Only 33% of those with at least 2 risk factors perceived themselves as being at higher risk.

These studies illustrate that a major awareness gap exists in terms of what osteoporosis actually is,
and how osteoporosis underpins fracture risk. A number of Disease Awareness Campaigns (DAC) have
been developed to provide the public with clear, evidence-based messages relating to osteoporosis
and reducing fracture risk. The 2Million2Many Campaign from the National Bone Health Alliance
(NBHA) in the United States provides an innovative example of implementing this approach [137]. The
key messages for 2Million2Many are very simple and compelling:
•

Every year, there are 2 million bone breaks that are no accident (in the USA).

•

They are the signs of osteoporosis in people as young as 50.

•

But only 2 out of 10 get a simple follow-up assessment.

•

Together we can break osteoporosis before it breaks us. But we must speak up. Remember:
-

Break a bone, request a test.

The impact of the 2Million2Many campaign cannot be assessed in isolation, because pursuant to the
launch of this campaign in 2012, NBHA and NOF launched a major FLS implementation initiative in
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2013 and a Qualified Clinical Data Registry focused on outcomes in osteoporosis and post-fracture
care in 2014 [137]. In 2015, the National Committee on Quality Assurance (NCQA) published The State
of Health Care Quality 2015 which reported on post-fracture osteoporosis care for women for the
period 2007 to 2014 [138]. The concurrence of the NBHA/NOF initiatives and an improvement in postfracture care in the United States is illustrated in figure 2.
In light of the widely documented secondary fracture prevention care gap described previously in this
review, the initial focus of DACs should be to drive awareness throughout the population of the world
that fracture begets fracture, and that appropriate assessment and intervention, where warranted,
can reduce the incidence of subsequent fractures.

Awareness of benefits and risks of osteoporosis treatments
During the last decade, treatment of osteoporosis has become embroiled in considerable controversy
in the media on account of reports of rare side effects in the clinical literature. Mass media coverage
of studies describing the incidence of osteonecrosis of the jaw (ONJ), atrial fibrillation (AF) and atypical
femur fractures (AFF) have caused alarm and confusion among patients and PCPs. The importance of
vigilant adverse event monitoring cannot be understated. However, healthcare professionals and their
patients must not lose sight of the fact that the risk-benefit analysis in individuals who are at high risk
of sustaining fragility fractures strongly favours treatment [139]. The current evidence-base regarding
the incidence of ONJ, AF and AFF can be summarised as follows:
•

ONJ: In 2015, an International Task Force estimated the incidence of ONJ in the osteoporosis
population to be 0.001% to 0.01%, which was marginally higher than the incidence observed
in the general population of <0.001% [140].

•

AF: In 2015, a systematic review and meta-analysis determined the effects of bisphosphonates
on AF, total adverse cardiovascular (CV) events, myocardial infarction (MI), stroke, and CV
death in adults with or at risk for low bone mass [141]. While the risk of AF was modestly but
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not significantly elevated for zoledronic acid exposure (6 trials; OR 1.24, 95% CI, 0.96–1.61), it
was not for oral bisphosphonates (26 trials; OR 1.02, 95% CI, 0.83–1.24).
•

AFF: In 2012, investigators from Kaiser Permanente in the United States analysed a large
population of bisphosphonate users to explore the relationship between duration of therapy
and risk of AFF [142]. Age-adjusted incidence rates for an AFF were 1.78 per 100,000 person
years (95% CI, 1.5-2.0) with exposure from 0.1 to 1.9 years, which increased to 113.1 per
100,000 person years (95% CI, 69.3-156.8) with exposure from 8 to 9.9 years. The authors
concluded that the incidence of AFF increases with longer duration of bisphosphonate use,
but this risk should be counterbalanced with the proven benefits in terms of fracture
reduction.

In 2016, an analysis of hip fracture patients insured by United HealthCare in the United States
observed that post-hip fracture bisphosphonate treatment had declined from 15% in 2004 to 3% in
the last quarter of 2013 [143]. During this period, the US Food and Drug Administration (FDA) issued
three drug safety announcements relating to bisphosphonates and ONJ (2005), AF (2007) and AFF
(2010). For the period 2003-2007, a 4% increase in bisphosphonate prescribing for hip fracture
patients was observed every quarter (OR 1.04, 95% CI, 1.02-1.07). Pursuant to the 2007 FDA
announcement on AF, this trend was reversed, with a 4% decrease in bisphosphonate use every
quarter (OR 0.94, 95% CI 0.93-0.99). This sequence of events is clearly at odds with global efforts,
including multisector collaboration in the United States through NBHA (a public-private partnership
with five government liaisons from FDA, the Centers for Disease Control and Prevention [CDC], Centers
for Medicare and Medicaid Services [CMS], National Aeronautics and Space Administration [NASA]
and National Institutes of Health [NIH]) [137], to prevent individuals who have sustained serious
fragility fractures from sustaining further and potentially life-threatening fractures. This experience
underscores the need for healthcare professionals, their professional organisations and regulatory
agencies to deliver balanced, tailored and meaningful information to patients regarding risk-benefit
ratios.
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Reimbursement and health system policy
In contrast with other comparable common non-communicable chronic diseases, osteoporosis has
often not attracted a commensurate level of attention from health providers and governments. This
section of the review will summarise findings relating to reimbursement and health system policy from
regional audits conducted during this decade by IOF. An overview of the current situation in North
America is also provided.

Access and reimbursement for osteoporosis assessment and treatment
Asia-Pacific
In 2013, IOF published the Asia-Pacific Regional Audit which provided an overview of the
epidemiology, costs and burden of osteoporosis for 16 jurisdictions: Australia, China, Chinese Taipei,
Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Pakistan, Philippines, Republic of Korea,
Singapore, Sri Lanka, Thailand and Vietnam [101]. This audit also provided information on access and
reimbursement for diagnosis and treatment of osteoporosis. While Australia, Hong Kong, Japan, New
Zealand, Republic of Korea and Singapore had 12-24 DXA machines per million of population, China,
India, Indonesia, Pakistan, Philippines, Sri Lanka and Vietnam were severely under-resourced with less
than 1 DXA machine per million of population. Further, BMD testing was not fully reimbursed in many
countries, which served as a barrier to accessing treatment. Reimbursement of osteoporosis
treatment varied greatly across the region, ranging from zero to 100% reimbursement for the most
commonly prescribed medications.

Eastern Europe and Central Asia
In 2010, IOF published the Eastern European and Central Asian Regional Audit which provided an
overview of the epidemiology, costs and burden of osteoporosis for 21 countries: Armenia, Azerbaijan,
Republic of Belarus, Bulgaria, Czech Republic, Estonia, Georgia, Hungary, Republic of Kazakhstan,
Kyrgyz Republic, Latvia, Lithuania, Republic of Moldova, Poland, Romania, Russian Federation,
Slovakia, Slovenia, Republic of Tajikistan, Ukraine and Republic of Uzbekistan [144]. The number of
DXA machines per million of population ranged from 20 in Slovenia to less than 1 in many Central
Asian countries. In most countries, BMD testing was only accessible in the main cities. However, more
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than 40% of the population resides in a rural area in about one third of the countries. Reimbursement
of osteoporosis treatment varied considerably between countries. In the Russian Federation, salmon
calcitonin was the only treatment available.

European Union
In 2013, IOF in collaboration with the European Federation of Pharmaceutical Industry Associations
(EFPIA) undertook a comprehensive osteoporosis and fragility fracture audit of the 27 EU member
states at the time [74, 75, 145]. The audit used a previous estimate that European countries required
11 DXA machines per million of population to provide adequate osteoporosis care [146]. Austria,
Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Italy, Portugal and Slovenia exceeded
this threshold, while 9 countries were considered to have very inadequate provision (Bulgaria, Czech
Republic, Hungary, Latvia, Lithuania, Luxembourg, Poland, Romania and the UK). Eighteen countries
offered unconditional reimbursement for DXA scanning. While most treatments were reimbursed in
most countries, full reimbursement without income conditions was provided in only 7 member states
(Austria, Germany, Italy, The Netherlands, Slovenia, Sweden and UK). In the remaining countries, the
level of reimbursement varied from zero in Malta up to 100% for selected treatments in Luxembourg
and Spain.

Latin America
In 2012, IOF published the Latin America Regional Audit which provided an overview of the
epidemiology, costs and burden of osteoporosis for 14 countries: Argentina, Bolivia, Brazil, Chile,
Columbia, Costa Rica, Cuba, Guatemala, Mexico, Nicaragua, Panama, Peru, Uruguay and Venezuela
[147]. Brazil and Chile had 10 DXA machines per million of population, while other countries ranged
from 0.9 to 6.7 per million of population. Access to BMD testing was often limited to urban areas
throughout the region. Bisphosphonates were widely available throughout the region with
considerable variability in reimbursement policy. Other osteoporosis therapies were also available,
but access was often restricted.
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Middle East and Africa
In 2011, IOF published the Middle East and Africa Regional Audit which provided an overview of the
epidemiology, costs and burden of osteoporosis for 17 countries: Bahrain, Egypt, Kuwait, Iran, Iraq,
Jordan, Kenya, Lebanon, Morocco, Palestine, Qatar, Saudi Arabia, South Africa, Syria, Tunisia, Turkey,
United Arab Emirates [148]. The number of DXA machines per million of population ranged from 27
in Lebanon to zero in Kenya. In most countries, BMD testing was only accessible in urban areas.
Reimbursement for DXA scanning and osteoporosis treatment varied widely throughout the region.

North America
IOF has not conducted an audit in North America. Accordingly, the authors of this review sought a
current summary of access and reimbursement for osteoporosis assessment and treatment from
Osteoporosis Canada (Personal communication: D. Theriault) and National Osteoporosis Foundation
in the United States (Personal communication: D. Lee).
In Canada there is no single national healthcare system. Healthcare falls under the independent
jurisdiction of each of the 10 provinces and 3 territories. There is reimbursement for many of the oral
bisphosphonates in all Canadian provinces for seniors who are indicated for such treatment. However,
coverage for other osteoporosis medications such as denosumab and zoledronic acid is quite variable
depending on the province/territory.
In the United States, reimbursement for screening, treatment and other bone health interventions
varies greatly depending on each patient’s health plan. To address these gaps, NBHA will convene a
bone health ‘payer summit’ in 2017 comprising the major payers to solicit their feedback on the
scientific and clinical evidence needed to reconsider these coverage and reimbursement decisions.
This feedback will be used to inform the development of an evidence report that will provide evidence
of the cost-effectiveness of these interventions to reduce future fracture risk.

Fragility fracture prevention in national policy
As for the previous section of this review, the IOF regional audits provide comprehensive information
on the level of priority afforded to fragility fracture prevention by governments in the various regions
35

of the world, which is summarised in table 8 [67, 74, 75, 101, 144, 145, 147, 148]. With regard to the
current situation in North America, Osteoporosis Canada (Personal communication: D. Theriault) and
the National Osteoporosis Foundation in the United States (Personal communication: D. Lee) have
provided summaries.
In Canada, provincial healthcare administrators are becoming increasingly aware of the compelling
benefits of FLS in reducing the fracture burden and the associated healthcare costs. OC has launched
a FLS Registry to showcase Canadian FLS meeting all 8 of the Essential Elements for Fracture Liaison
Services [149].
In the United States, health care reform is evolving from fee for service to supporting improved quality,
prevention and care coordination with financial incentives (or penalties) to encourage healthcare
professionals and health systems to report on and improve patient outcomes. There are a number of
quality measures focused on osteoporosis and post-fracture care but performance around these
measures remains low compared to other major chronic diseases. Further, a major drop in
reimbursement for DXA scans performed in the office setting has led to a drop in the number of
providers and more than 1 million less DXA scans performed per annum.

Fracture epidemiology in the developing world
It is well recognised in the literature that in the coming decades the burden of fragility fractures will
increasingly be borne by older people living in the developing world [150]. The IOF regional audits
noted a dearth of data pertaining to fracture epidemiology in many developing countries [101, 144,
147, 148]. Arguably, the most obvious example of this challenge is India, which is poised to become
the world’s most populous country in the next few decades. The 2013 IOF Asia-Pacific audit identified
the pressing need for multicentre, large-scale hip fracture incidence studies to be conducted [101]. In
due course, efforts by the Indian Society for Bone and Mineral Research (ISBMR) will provide robust
fracture epidemiology to inform development of policy on fracture prevention in India. Similar
initiatives are needed in Malaysia, Pakistan, Sri Lanka, Thailand and Vietnam.
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In the course of the development of new FRAX® models, epidemiological estimates of the incidence
of fractures have become available for major countries such as Brazil [151] and the Russian Federation
[152]:
•

Brazil: In 2015, there were estimated to be 80,640 hip fractures in Brazil, of which 23,422 were
in men and 57,218 in women. In 2040, the number of hip fractures is expected to rise to 55,844
in men and 141,925 in women, a rise of 238 and 248 %, respectively.

•

Russian Federation: Extrapolation of robust fracture information collected in Yaroslavl and
Pervouralsk to the entire population of the Russian Federation suggests that 112,000 hip
fractures occurred in 2010. This was expected to rise to 159,000 in 2035. The estimated
number of major osteoporotic fractures was expected to rise from 590,000 to 730,000 over
the same time interval. Further large scale, multi-centre epidemiological studies should be
conducted in Russia to confirm these estimates.

Provision of robust epidemiological estimates of fracture incidence throughout Asia-Pacific, Central
Asia, Latin America, the Middle East and Africa will be a critical step towards supporting development
of fracture prevention policies for these rapidly aging populations.

Summary and Call to Action
The first of the Baby Boomer generation began to retire in 2011. At that time, an editorial in this
journal noted that 450 million people would celebrate their 65th birthday during the subsequent two
decades [150]. Today, in 2016, a good number of them already have done so. In the absence of
implementation of an evidence-based, multidisciplinary, system-wide, global response, osteoporosis
and the fragility fractures it causes will impose a catastrophic burden on our older people, their
families and carers, and our health and social care systems. However, this is a catastrophe that can be
averted.
This review has outlined a stepwise approach to case-finding individuals who are at high risk of
sustaining fragility fractures. By first closing the secondary fracture prevention care gap, up to half of
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individuals who would otherwise fracture their hip could be treated to prevent this debilitating and
costly injury. Integration of bone health and falls risk assessments into the management of individuals
who take medicines which have adverse effects on bone must become standard practice. Similarly,
individuals who are diagnosed with diseases which feature osteoporosis as a common comorbidity
need to receive care that will minimise their fracture risk. When the needs of these obviously high risk
groups have been addressed, we must turn our attention to development of cost-effective strategies
to prevent the first major osteoporotic fracture.
Public awareness of osteoporosis must be increased dramatically throughout the world. Effective
disease awareness campaigns are needed to ensure that when an older person sustains a fragility
fracture, their first thought – and that of their family and friends – is ‘Did that bone break because of
osteoporosis?’ Health professionals and their organisations, national patient societies, health system
leaders and regulatory agencies must work together to craft clear, balanced communications
concerning the benefits and risks of treatments, and the implications of choosing not to take
treatment recommended by a clinician.
Finally, all governments need to establish osteoporosis as a national health priority, with
commensurate human and financial resources to ensure that best practice is delivered for all patients
in their jurisdictions. Where the current disease burden is not known, studies to close such evidence
gaps must be commissioned forthwith.
We cannot ignore the current and growing burden that osteoporosis and fragility fractures impose
upon our global society. This review clearly illustrates that we have the knowledge and tools that we
need to manage bone health optimally for all. The time has come to make that possibility a reality.
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Figure legends
Figure 1. A systematic approach to fragility fracture care and prevention for New Zealand [66, 67]
Reproduced with kind permission of Osteoporosis New Zealand

Figure 2. Post-fracture osteoporosis assessment and/or treatment in the United States [138]
Footnote beneath figure 2:
n.b. The data presented is for the Healthcare Effectiveness Data and Information Set (HEDIS®)
measure Osteoporosis Management in Women Who Had a Fracture. This represents the percentage
of women aged 65 to 85 years who sustained a fracture and who had either a BMD test or a
prescription for a drug to treat osteoporosis in the six months after the fracture.
Reproduced with permission from The State of Health Care Quality Report 2015 by the National
Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the National
Committee for Quality Assurance (NCQA). To obtain a copy of this publication, contact NCQA
Customer Support at +1-888-275-7585 or www.ncqa.org/publications.
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Table 1. Statistically significant findings (p<0.05) of Cochrane systematic reviews for secondary
fracture prevention with oral bisphosphonates for postmenopausal women
Treatment

Alendronated
Etidronatee
Risedronatef

a.
b.
c.
d.
e.
f.

Hip fracture
reduction (%)
RRRa
(95% CIc)
53
(15-74)
-

ARRb

26
(6-41)

1

1
-

Vertebral fracture
reduction (%)
RRR
(95% CI)
45
(31-57)
47
(13-68)
39
(24-50)

ARR
6
5
5

Non-vertebral
fracture reduction
(%)
RRR
ARR
(95% CI)
23
2
(8-36)
20
(10-28)

2

Reference

Wells et al
[11]
Wells et al
[12]
Wells et al
[13]

RRR = Relative Risk Reduction
ARR = Absolute Risk Reduction
CI = Confidence Interval
10 mg daily dose
400 mg daily dose
5 mg daily dose

Table 2. Fracture Liaison Service models of care of varying intensity and outcomes [33]
FLS Model
Type A: 3i FLS model
Type B: 2i FLS model
Type C: 1i FLS model
Type D: ‘Zero I’ FLS model

Proportion investigated with
BMD testing
79%
60%
43%
-

Proportion initiated on
osteoporosis treatment
46%
41%
23%
8%

Reproduced with kind permission of Springer

Table 3. Vertebral fractures as a proportion of Fracture Liaison Service case loads
Country
Australia
Canada
Netherlands
Switzerland
UK

FLS location

Vertebral fractures (%)

Reference

Royal Newcastle
Hospital
St. Michael’s Hospital,
Toronto
Eindhoven
University Hospitals of
Geneva
Cambridge

1.6

Giles et al [38]

1.7

Bogoch et al [39]

5.4
5.5

Blonk et al [40]
Chevalley et al [41]

0.1

Premaor et al [42]
48

UK
UK
USA

Glasgow
Ipswich
University of
Wisconsin

2
1.8
6.1

McLellan et al [43]
Clunie et al [44]
Harrington et al [45]

Reproduced with kind permission of Optasia Medical Ltd

Table 4. Proportion of women in European countries with and without prior fracture history in 2010
Country

Women aged
≥50 yearsa

Women with prior
history of ≥1
fracturea (%)

Women without
prior fracture historya
(%)

Reference

12,200
17,661
12,900
1,836
11,494

1,272 (10.4)
2,490 (14.1)
2,093 (16.2)
0.418 (22.8)b
1,544 (13.4)

10,928 (89.6)
15,171 (85.9)
10,807 (83.8)
1,418 (77.2)
9,950 (86.6)

Cawston et al [70]
Gauthier et al [71]
Piscitelli et al [72]
Gauthier et al [69]
Gauthier et al [73]

France
Germany
Italy
Sweden
UK
a.
b.

In thousands
Value for 2010 estimated by creation of linear series based on values for 2009 and 2020 specified in
publication

Table 5. Relative proportions of women and men in European countries with a prior history of hip or
vertebral fracture in 2010 [74]
Country

Women
aged ≥50
yearsa

Men
aged ≥50
yearsa

France

12,358

10,287

Germany

17,764

15,246

Italy

12,997

10,791

Sweden

1,830

1,659

UK

11,534

10,102

a.

Prior history of hip
fracturea
Women
Men (%)
(%)
328.7
106.0
(2.7)
(1.0)
489.5
180.3
(2.8)
(1.2)
384.5
132.6
(3.0)
(1.2)
66.6
32.4
(3.6)
(2.0)
293.1
125.8
(2.5)
(1.2)

Ratio of
%
women
to % men
2.7
2.3
2.5
1.8
2.1

Prior history of
vertebral fracturea
Women
Men (%)
(%)
310.9
124.6
(2.5)
(1.2)
555.6
219.9
(3.1)
(1.4)
387.6
151.4
(3.0)
(1.4)
74.4
36.9
(4.1)
(2.2)
292.1
145.4
(2.5)
(1.4)

Ratio of
%
women
to % men
2.1
2.2
2.1
1.9
1.8

In thousands
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Table 6. Drug classes associated with bone loss and/or fragility fractures
Drug class

Loss of BMD [81]

Increased fracture risk [81]

Androgen deprivation
therapy

Gonadotropin-releasing
hormone agonists (GnRHs) are
the most commonly used ADT.
BMD declines by 2-5% during the
first year of ADT.
Long-term heparin use leads to
loss of BMD. Up to 30% of
heparin-treated pregnant
women lose BMD.

The risk of hip and vertebral
fractures increases to 20-50% after
5 years of ADT. Fracture risk
correlates with age, rate of BMD
loss and ADT exposure.
2.2-3.6% of heparin-treated
pregnant women sustain fractures.
15% of non-pregnant women longterm users sustain vertebral
fractures.
Meta-analysis has shown treatment
with ACs to be associated with
increased fracture risk, with a
relative risk (RR) of 2.2. Fracture
risk is dependent on duration and
dose.
Women treated with AIs have a
30% higher fracture risk than agematched healthy women. AI users
sustain more peripheral fractures
than hip or vertebral fractures [85].
Several studies suggest that CIs are
associated with fragility fractures in
a dose and duration dependent
fashion.
30-50% of patients receiving GCs
develop fractures. GC-induced
osteocyte apoptosis leads to early
increase in fracture risk prior to loss
of BMD.
Depot MPA is associated with a
slight increase in fracture risk.
More studies are needed to
definitively assess the impact on
fracture risk.
PPIs use is associated with a
modest increase in fracture risk.
Fracture risk appears to be related
to duration of PPI use.

Bienz and Saad [82]

Two meta-analyses have reported
the adjusted odds ratio for fracture
among SSRI users to be approx. 1.7.
Fracture risk is dependent on dose
and duration of SSRI treatment.

Rizzoli et al [90]

Two meta-analyses have reported
that TZDs significantly increase
fracture incidence in women with
Type 2 diabetes, but not in men.
Notably, fracture risk is increased in
young women without risk factors.

Napoli et al [91]

Anticoagulants

Anticonvulsants

In epilepsy, ACs are associated
with bone loss in men >65 years
and postmenopausal women.
Phenytoin has been associated
with BMD loss in young women.

Aromatase inhibitors

The annual rate of bone loss in
women taking AIs is approx. 2.5%
as compared to 1-2% for healthy
postmenopausal women [85].

Calcineurin inhibitors

The direct effect of CIs on BMD is
not clear due to post-transplant
GC use and compromised bone
health before transplants.
While all recipients of GCs are at
increased risk of bone loss, older
men and postmenopausal
women are at highest risk with
GC doses of >20 mg daily.
Depot MPA has been shown to
reduce BMD by 2-8%. Bone loss
is rapid during the first 2 years of
treatment then stabilises.

Glucocorticoids

Medroxyprogesterone
acetate

Proton pump
inhibitors

Selective serotonin
reuptake inhibitors

Thiazolidinediones

There is no clear association
between PPI use and loss of
BMD. The mechanism by which
PPIs increase fracture risk is
unknown.
Small studies have found an
association between SSRI use
and bone loss. However, metaanalysis has reported SSRIrelated fractures in the absence
of bone loss.
TZDs reduce bone formation
through impairing differentiation
of osteoblast precursors, and
increase resorption through
several mechanisms, resulting in
bone loss.

Literature review

Coppola et al [83]

van der Kruijs et al [84]

Rizzoli et al [85]

Lan et al [86]

Whittier and Saag [87]

Lopez et al [88]

Lau et al [89]
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Table 7. Examples of diseases associated with bone loss and/or fragility fractures
Disease

Global prevalence
(millions)

Evidence for increased risk
of bone loss or fractures

Diabetes

415 [107]

Chronic obstructive
pulmonary disease
(COPD)

65 [108]

Meta-analyses have shown both Type 1 and Type
2 diabetics to be at increased risk of hip fracture
[113, 114]. Relative risk (RR) for Type 1 is 6.3-6.9
and RR for Type 2 is 1.4-1.7 [114].
Systematic literature review established the
average prevalence of osteoporosis among COPD
patients to be 35% [115]. The prevalence of
vertebral fractures is high, ranging from 49-63%
dependent on GC use [116].
A UK study evaluated fracture risk in people with
celiac disease. The overall hazard ratio for any
fracture was 1.30 (95% CI, 1.16-1.46), for hip
fracture was 1.90 (95% CI, 1.20-3.02), and for
ulna or radius fracture was 1.77 (95% CI, 1.352.34) [117].
A large cohort (n=6,027) with IBD in Canada had
40% higher fracture incidence than the general
population [118].
In the UK, incidence of hip fracture among
patients with Alzheimer’s disease is 3 times
higher than amongst cognitively healthy peers
[119].

Diseases of
malabsorption

42 (Celiac) [109]
5 (IBDa) [110]

Dementia

44 [111]

Rheumatoid
arthritis (RA)

17 [112]

a.

A large UK study (n=30,000) compared fracture
incidence of RA patients to a control group. The
RA patients’ risk of hip fracture and vertebral
fracture was increased 2-fold and 2.4-fold,
respectively [120].

Evidence for
osteoporosis care gap

Disease specific bone
health guidelines

There is currently a lack of studies on the
proportion of diabetics receiving bone health
assessment.

No

Among a large cohort (n=12,646) of men with
hip fracture in the US Veteran’s Health Affairs
system, nearly half (47.6%) had COPD [121].
Osteoporosis was known pre-fracture in only 3%
of subjects.
Studies from Austria [122] and the United States
[123] have reported that approximately one
quarter of IBD patients underwent BMD testing.

The Netherlands [126]

Studies from several countries report that
osteoporosis is infrequently diagnosed and
treated in people living with dementia e.g.
Canada. Among a large cohort (n=39,452)
treated for osteoporosis, a diagnosis of
dementia was a negative predictor of treatment
(adjusted Odds Ratio 0.55, 95% CI 0.44-0.69)
[124].
Studies from several countries report suboptimal assessment and/or treatment of
osteoporosis in RA patients e.g. USA. Less than
half of a large cohort (n=9,600) of veterans with
RA received preventive treatment for
osteoporosis [125].

No

Several national guidelines e.g. UK
[127]

Several national guidelines and
EULAR [128]

IBD = Inflammatory Bowel Diseases (i.e. Crohn’s disease and ulcerative colitis)
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Table 8. Fragility fracture prevention in national policy
Region

Countries with osteoporosis as

References

a national health priority
Asia-Pacific

Australia, China, Chinese

IOF 2013 [101]

Taipei, New Zealanda,
Singapore. 5/16 countries.
Eastern Europe and Central

Republic of Belarus, Bulgaria.

Asia

2/21 countries.

European Union

Bulgaria, Finland, France, Italy,

IOF 2010 [144]

IOF-EFPIA 2013 [74, 75, 145]

Luxembourg, Portugal,
Romania, Sweden, UK. 9/27
member states.
Latin America

Brazil, Cuba, Mexico. 3/14

IOF 2012 [147]

countries.
Middle East and Africa

Iran, Iraq and Jordan. 3/17

IOF 2011 [148]

countries.

a. Significant progress has been made in New Zealand since the 2013 IOF Asia-Pacific Audit [67]
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